A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Search:
Medline
CancerConsultants.com
Both
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here
Conference Coverage
Date: December 6-9, 2008
Location: San Francisco, CA
Author:

Advances in the Treatment of Myelodysplastic Syndromes
Dean Buckner, MD, Medical Editor, Cancer Consultants, Inc

Autologous Transplants for Multiple Myeloma: Updates from the 2008 American Society of Hematology Meeting
Dean Buckner, MD, Medical Editor, Cancer Consultants, Inc

Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma
Charles H. Weaver, MD, Medical Editor, Cancer Consultants, Inc

Advances in the Treatment of Low-Grade Non-Hodgkin’s Lymphoma (NHL)
Charles H. Weaver, MD, Medical Editor, Cancer Consultants, Inc

Developments in the Treatment of Acute Lymphoblastic Leukemia
Dean Buckner, MD, Medical Editor, Cancer Consultants, Inc

Developments in the Treatment of Acute Myeloid Leukemia
Dean Buckner, MD, Medical Editor, Cancer Consultants, Inc

New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma (NHL)
Charles H. Weaver, MD, Medical Editor, Cancer Consultants, Inc

New Agents for the Treatment of Multiple Myeloma: A Report from the 2008 American Society of Hematology Meeting
Dean Buckner, MD, Medical Editor, Cancer Consultants, Inc

Updates in Management of ITP from ASH
Jenny Maxon, Senior Writer, Cancer Consultants, Inc

Newsletters
Register in our member center today to receive a monthly newsletter with conference coverage updates.
Learn More »
Practice Resources
Learn how to have our conference coverage on your website.
Learn More »
Related News Stories
Maintenance Rituxan® Is Safe for Follicular Lymphoma (7/8/2008)

Gemcitabine, Rituximab, Oxaliplatin, and Pegfilgrastim Active for Relapsed NHL (6/27/2008)

Lumiliximab and FCR Promising for Relapsed CLL (6/26/2008)

Flavopiridol Has Significant Activity in Relapsed Chronic Lymphocytic Leukemia (6/25/2008)

Sprycel® Effective for Patients with Newly Diagnosed CML (6/24/2008)

Tasigna® Effective for Patients with Newly Diagnosed CML (6/24/2008)

Patients with KRAS Mutation Do Not Benefit from EGFR Inhibitors (6/20/2008)

Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer (6/20/2008)

Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure? (6/19/2008)

Radiation Therapy for Prostate Cancer Increases Incidence of AML (6/18/2008)

Quinamed® + ARA-C Effective for Secondary Acute Myeloid Leukemia (6/17/2008)

Statins May Reduce Acute Graft-versus-host Disease (6/17/2008)

Provigil®, a Eugeroic Agent, Improves Severe Cancer-related Fatigue (6/13/2008)

Results of Treating NHL Patients over the Age of 80 Reported at ASCO (6/12/2008)

Single-dose Carboplatin Confirmed as Effective as Radiation Therapy for Stage I Seminoma (6/12/2008)

Dose-dense Chemotherapy Effective for Localized Ewing’s Sarcoma (6/11/2008)

Mayo Clinic Reports Increasing Use of Mastectomy for Early-stage Breast Cancer (6/11/2008)

Brachytherapy May Be Treatment of Choice for Endometrial Cancer (6/10/2008)

Gemzar® Improves Survival in Early Pancreatic Cancer (6/9/2008)

Addition of Tykerb® to Herceptin® Improves Time to Progression in Herceptin Pre-treated Breast Cancer (6/6/2008)

Addition of Avastin® to Taxotere® Improves Progression-free Survival in Advanced HER2-negative Breast Cancer (6/6/2008)

Nexavar® Delays Progression of Heavily Pre-treated NSCLC (6/6/2008)

Acupuncture Reduces Pain after Neck Dissection (6/6/2008)

VePesid®/Platinol® Remains Standard of Care for Small Cell Lung Cancer (6/6/2008)

Blood Test Shows Promise for Early Detection of Lung Cancer (6/6/2008)

Tykerb® Monotherapy Active in HER2-positive Refractory Inflammatory Breast Cancer (6/6/2008)

CDX-110 Vaccine May Improve Survival in Brain Cancer (6/5/2008)

Sites of Relapse in Breast Cancer May Require Biopsy to Accurately Determine HER2 or Hormone Status (6/5/2008)

Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Renal Cell Cancer (6/4/2008)

Conventional Chemotherapy Outperforms Xeloda® in Older Breast Cancer Patients (6/4/2008)

More Conference Coverage News »
Additional Resources
Information by Cancer Type



© 1998-2007 CancerConsultants.com  All Rights Reserved.